NO2018026I1 - Bictegravir eller et farmasøytisk akseptabelt salt derav, spesielt natriumbictegravir - Google Patents

Bictegravir eller et farmasøytisk akseptabelt salt derav, spesielt natriumbictegravir

Info

Publication number: NO2018026I1
Authority: NO; Norway
Prior art keywords: bictegravir; pharmaceutically acceptable; acceptable salt; especially sodium; sodium
Prior art date: 2012-12-21

Application number

NO2018026C

Other languages

English (en)

Other versions

NO2018026I2 (no

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-12-21

Filing date

2018-08-23

Publication date

2018-08-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2018026(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-08-23 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2018-08-23 Publication of NO2018026I2 publication Critical patent/NO2018026I2/no

2018-08-23 Publication of NO2018026I1 publication Critical patent/NO2018026I1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO2018026C 2012-12-21 2018-08-23 Bictegravir eller et farmasøytisk akseptabelt salt derav, spesielt natriumbictegravir NO2018026I1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261745375P	2012-12-21	2012-12-21
US201361788397P	2013-03-15	2013-03-15
US201361845803P	2013-07-12	2013-07-12
PCT/US2013/076367 WO2014100323A1 (en)	2012-12-21	2013-12-19	Polycyclic-carbamoylpyridone compounds and their pharmaceutical use

Publications (2)

Publication Number	Publication Date
NO2018026I2 NO2018026I2 (no)	2018-08-23
NO2018026I1 true NO2018026I1 (no)	2018-08-23

Family

ID=49917297

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO2018026C NO2018026I1 (no)	2012-12-21	2018-08-23	Bictegravir eller et farmasøytisk akseptabelt salt derav, spesielt natriumbictegravir

Country Status (42)

Country	Link
US (6)	US9216996B2 (no)
EP (4)	EP4122935A1 (no)
JP (6)	JP6028105B2 (no)
KR (8)	KR101770048B1 (no)
CN (4)	CN111303152B (no)
AP (1)	AP2015008510A0 (no)
AR (1)	AR094197A1 (no)
AU (6)	AU2013361401C1 (no)
BR (2)	BR112015014714B1 (no)
CA (3)	CA3012242C (no)
CL (3)	CL2015001756A1 (no)
CR (2)	CR20170279A (no)
CY (3)	CY1117570T1 (no)
DK (3)	DK2822954T3 (no)
EA (2)	EA030003B1 (no)
ES (3)	ES2926068T3 (no)
HK (3)	HK1205124A1 (no)
HR (3)	HRP20220899T1 (no)
HU (4)	HUE046559T2 (no)
IL (4)	IL239316A (no)
LT (3)	LT3608325T (no)
LU (1)	LUC00083I2 (no)
MD (3)	MD4754C1 (no)
ME (1)	ME02400B (no)
MX (4)	MX357940B (no)
MY (2)	MY164352A (no)
NL (1)	NL300947I2 (no)
NO (1)	NO2018026I1 (no)
NZ (2)	NZ709260A (no)
PE (2)	PE20151499A1 (no)
PH (3)	PH12019501848A1 (no)
PL (3)	PL3067358T3 (no)
PT (3)	PT3608325T (no)
RS (1)	RS54873B1 (no)
SG (1)	SG11201504857SA (no)
SI (3)	SI3608325T1 (no)
SM (1)	SMT201600157B (no)
TW (5)	TWI642669B (no)
UA (2)	UA123572C2 (no)
UY (1)	UY35213A (no)
WO (1)	WO2014100323A1 (no)
ZA (2)	ZA201507997B (no)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9540343B2 (en)	2011-07-06	2017-01-10	Gilead Sciences, Inc.	Compounds for the treatment of HIV
UY34763A (es)	2012-04-26	2013-10-31	Bristol Myers Squibb Co	Inhibidores de la agregación plaquetaria
TWI568722B (zh)	2012-06-15	2017-02-01	葛蘭馬克製藥公司	作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
KR101770048B1 (ko)	2012-12-21	2017-08-21	길리애드 사이언시즈, 인코포레이티드	폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
UA111305C2 (uk)	2012-12-21	2016-04-11	Пфайзер Інк.	Конденсовані лактами арилу та гетероарилу
US9278950B2 (en)	2013-01-14	2016-03-08	Incyte Corporation	Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
SG10201705662WA (en)	2013-01-15	2017-08-30	Incyte Corp	Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
EP3252058B1 (en) *	2013-07-12	2021-01-20	Gilead Sciences, Inc.	Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
NO2865735T3 (no) *	2013-07-12	2018-07-21
JP2016528298A (ja)	2013-08-23	2016-09-15	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	Ｐｉｍキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物
ZA201503540B (en) *	2014-05-20	2016-10-26	Cipla Ltd	Process for preparing polycyclic carbamoyl pyridone derivatives
BR112016029612B1 (pt)	2014-06-17	2021-01-19	Pfizer Inc.	compostos de di-hidroisoquinolinona substituídos
TW201613936A (en)	2014-06-20	2016-04-16	Gilead Sciences Inc	Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (no) *	2014-06-20	2018-06-23
TWI677489B (zh) *	2014-06-20	2019-11-21	美商基利科學股份有限公司	多環型胺甲醯基吡啶酮化合物之合成
US9580418B2 (en)	2014-07-14	2017-02-28	Incyte Corporation	Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en)	2014-07-14	2017-11-21	Incyte Corporation	Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
JPWO2016027879A1 (ja) *	2014-08-22	2017-06-01	塩野義製薬株式会社	インテグラーゼ阻害活性を有する多環性ピリドン誘導体
WO2016036759A1 (en)	2014-09-04	2016-03-10	Gilead Sciences, Inc.	Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
WO2016090545A1 (en) *	2014-12-09	2016-06-16	Merck Sharp & Dohme Corp.	Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
TWI695003B (zh) *	2014-12-23	2020-06-01	美商基利科學股份有限公司	多環胺甲醯基吡啶酮化合物及其醫藥用途
ES2705709T3 (es)	2014-12-24	2019-03-26	Gilead Sciences Inc	Compuestos de isoquinolina para el tratamiento del VIH
TW202237569A (zh)	2014-12-24	2022-10-01	美商基利科學股份有限公司	喹唑啉化合物
US9701677B2 (en)	2014-12-24	2017-07-11	Gilead Sciences, Inc.	Fused pyrimidine compounds
JP7381190B2 (ja)	2014-12-26	2023-11-15	エモリー・ユニバーシテイ	Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
ES2801380T3 (es)	2015-03-04	2021-01-11	Gilead Sciences Inc	Compuestos de 4,6-diamino-pirido [3,2-d] pirimidina y su utilización como moduladores de receptor de tipo toll
ES2718410T3 (es)	2015-04-02	2019-07-01	Gilead Sciences Inc	Compuestos de carbamoilpiridonas policíclicos y su utilización farmacéutica
DK3428170T3 (da) *	2015-04-28	2021-03-01	Shionogi & Co	Anti-influenza polycyklisk pyridonderivat og prodrug deraf
WO2016196244A1 (en)	2015-05-29	2016-12-08	Incyte Corporation	Pyridineamine compounds useful as pim kinase inhibitors
CA2995004A1 (en)	2015-08-26	2017-03-02	Gilead Sciences, Inc.	Deuterated toll-like receptor modulators
TWI734699B (zh)	2015-09-09	2021-08-01	美商英塞特公司	Ｐｉｍ激酶抑制劑之鹽
US10059697B2 (en)	2015-09-30	2018-08-28	Gilead Sciences, Inc.	Compounds and combinations for the treatment of HIV
TW201718546A (zh)	2015-10-02	2017-06-01	英塞特公司	適用作pim激酶抑制劑之雜環化合物
EA201890654A1 (ru)	2015-11-09	2018-10-31	Джилид Сайэнс, Инк.	Терапевтические композиции для лечения вируса иммунодефицита человека
TWI814056B (zh)	2015-12-15	2023-09-01	美商基利科學股份有限公司	人類免疫不全病毒中和抗體
CN109562107A (zh)	2016-05-10	2019-04-02	C4医药公司	用于靶蛋白降解的杂环降解决定子体
EP3455218A4 (en)	2016-05-10	2019-12-18	C4 Therapeutics, Inc.	C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197036A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	Spirocyclic degronimers for target protein degradation
WO2018005328A1 (en) *	2016-06-27	2018-01-04	Concert Pharmaceuticals, Inc.	Deuterated bictegravir
KR20240070646A (ko)	2016-08-19	2024-05-21	길리애드 사이언시즈, 인코포레이티드	Hiv 바이러스 감염의 예방적 또는 치유적 치료에 유용한 치료 화합물
WO2018042331A1 (en)	2016-08-31	2018-03-08	Glaxosmithkline Intellectual Property (No.2) Limited	Combinations and uses and treatments thereof
WO2018042332A1 (en)	2016-08-31	2018-03-08	Glaxosmithkline Intellectual Property (No.2) Limited	Combinations and uses and treatments thereof
WO2018045150A1 (en)	2016-09-02	2018-03-08	Gilead Sciences, Inc.	4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
KR102268448B1 (ko)	2016-09-02	2021-06-22	길리애드 사이언시즈, 인코포레이티드	톨 유사 수용체 조정제 화합물
WO2018051250A1 (en)	2016-09-14	2018-03-22	Viiv Healthcare Company	Combination comprising tenofovir alafenamide, bictegravir and 3tc
WO2018064071A1 (en)	2016-09-27	2018-04-05	Gilead Sciences, Inc.	Therapeutic compositions for treatment of human immunodeficiency virus
WO2018064080A1 (en)	2016-09-28	2018-04-05	Gilead Sciences, Inc.	Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection
EP3532478B1 (en)	2016-10-27	2021-05-26	Gilead Sciences, Inc.	Crystalline form of darunavir free base
JOP20190130A1 (ar)	2016-12-02	2019-06-02	Merck Sharp & Dohme	مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
CN108250215B (zh) *	2016-12-28	2022-04-19	华创合成制药股份有限公司	一种新型抗hiv药物及其制备方法和用途
TWI714820B (zh)	2017-01-31	2021-01-01	美商基利科學股份有限公司	替諾福韋艾拉酚胺(tenofovir alafenamide)之晶型
JOP20180009A1 (ar)	2017-02-06	2019-01-30	Gilead Sciences Inc	مركبات مثبط فيروس hiv
CN106860464A (zh) *	2017-02-16	2017-06-20	江苏艾迪药业有限公司	用于联合抗病毒治疗的药物组合物及应用
CN106860414B (zh) *	2017-02-16	2019-12-24	江苏艾迪药业股份有限公司	一种用于抗hiv的复方制剂及其制备方法与应用
WO2018229798A1 (en)	2017-06-13	2018-12-20	Cipla Limited	Process for the preparation of bictegravir and intermediate thereof
US10882907B2 (en)	2017-06-21	2021-01-05	Gilead Sciences, Inc.	Multispecific antibodies that target HIV GP120 and CD3
WO2019027920A1 (en)	2017-08-01	2019-02-07	Gilead Sciences, Inc.	CRYSTALLINE FORMS OF ETHYL ((S) - (((((2R, 5R) -5- (6-AMINO-9H-PURIN-9-YL) -4-FLUORO-2,5-DIHYDROFURAN-2-YL) OXY ) METHYL) (PHENOXY) PHOSPHORYL) -L-ALANINATE (GS-9131) FOR THE TREATMENT OF VIRAL INFECTIONS
US20200246351A1 (en)	2017-08-09	2020-08-06	Viiv Healthcare Company	Combinations and uses and treatments thereof
EP3664895A4 (en)	2017-08-09	2021-06-30	VIIV Healthcare Company	COMBINATIONS AS WELL AS USES AND TREATMENTS THEREOF
AR112412A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas de sal de colina de un inhibidor de la cápside del vih
TW202024061A (zh)	2017-08-17	2020-07-01	美商基利科學股份有限公司	Hiv蛋白質膜抑制劑之固體形式
CN111386276B (zh) *	2017-10-06	2023-06-23	盐野义制药株式会社	制备取代的多环吡啶酮衍生物的立体选择性方法
JOP20180092A1 (ar)	2017-10-13	2019-04-13	Gilead Sciences Inc	مثبطات hiv بروتياز
EP3700573A1 (en)	2017-10-24	2020-09-02	Gilead Sciences, Inc.	Methods of treating patients co-infected with a virus and tuberculosis
CN118477088A (zh)	2017-12-07	2024-08-13	埃默里大学	N4-羟基胞苷及衍生物和与其相关的抗病毒用途
US10596161B2 (en)	2017-12-08	2020-03-24	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
US10966999B2 (en)	2017-12-20	2021-04-06	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US11203610B2 (en)	2017-12-20	2021-12-21	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
KR102497051B1 (ko) *	2018-01-19	2023-02-09	길리애드 사이언시즈, 인코포레이티드	빅테그라비르의 대사물
ES2916405T3 (es)	2018-02-09	2022-06-30	Sandoz Ag	Forma cristalina de bictegravir sódico
CN111836805B (zh)	2018-02-15	2023-07-14	吉利德科学公司	吡啶衍生物及其用于治疗hiv感染的用途
WO2019159199A1 (en)	2018-02-16	2019-08-22	Cipla Limited	Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
TWI823164B (zh)	2018-02-16	2023-11-21	美商基利科學股份有限公司	用於製備有療效化合物之方法及中間物
TWI818007B (zh)	2018-04-06	2023-10-11	捷克科學院有機化學與生物化學研究所	2'3'-環二核苷酸
TW202005654A (zh)	2018-04-06	2020-02-01	捷克科學院有機化學與生物化學研究所	２，２，─環二核苷酸
TWI833744B (zh)	2018-04-06	2024-03-01	捷克科學院有機化學與生物化學研究所	3'3'-環二核苷酸
CN109020911B (zh) *	2018-04-16	2022-06-28	常州制药厂有限公司	用于制备bictegravir的中间体及其制备方法
CA3098274A1 (en)	2018-04-26	2019-10-31	Mylan Laboratories Limited	Polymorphic forms of bictegravir and its sodium salt
TW202014193A (zh)	2018-05-03	2020-04-16	捷克科學院有機化學與生物化學研究所	包含碳環核苷酸之2’3’－環二核苷酸
CN110526930B (zh) *	2018-05-23	2022-06-03	莫云芬	抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
WO2019230857A1 (ja)	2018-05-31	2019-12-05	塩野義製薬株式会社	多環性ピリドン誘導体
MD3805220T2 (ro)	2018-05-31	2024-10-31	Shionogi & Co Ltd	Derivat policiclic de carbamoilpiridonă
JP7307412B2 (ja)	2018-06-27	2023-07-12	国立大学法人北海道大学	多環性カルバモイルピリドン誘導体を含有するアレナウイルス増殖阻害剤
US11623933B2 (en)	2018-06-28	2023-04-11	Honour Lab Limited	Process for the preparation of sodium (2R,5S,13AR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl) carbamoyl)-2,3,4,5,7,9,13,13A-octahydro-2,5-Methanopyrido[1 ′,2′:4,5]pyrazino[2,1 -b] [1,3] oxazepin-8-olate and its polymorphic form
NZ771700A (en)	2018-07-03	2024-07-05	Gilead Sciences Inc	Antibodies that target hiv gp120 and methods of use
ES2975333T3 (es)	2018-07-12	2024-07-04	Laurus Labs Ltd	Un proceso para la purificación de derivados policíclicos de carbamoilpiridona protegidos
CA3103522C (en)	2018-07-16	2023-11-21	Gilead Sciences, Inc.	Capsid inhibitors for the treatment of hiv
TWI829205B (zh)	2018-07-30	2024-01-11	美商基利科學股份有限公司	抗hiv化合物
EP3852761A1 (en)	2018-09-19	2021-07-28	Gilead Sciences, Inc.	Integrase inhibitors for the prevention of hiv
EP3860717A1 (en)	2018-10-03	2021-08-11	Gilead Sciences, Inc.	Imidozopyrimidine derivatives
JP7437051B2 (ja) *	2018-10-22	2024-02-22	ボードオブリージェンツオブザユニバーシティオブネブラスカ	抗ウイルスプロドラッグおよびそのナノ製剤
TWI721624B (zh)	2018-10-31	2021-03-11	美商基利科學股份有限公司	經取代之6-氮雜苯并咪唑化合物
EP3873903B1 (en)	2018-10-31	2024-01-24	Gilead Sciences, Inc.	Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
EP3653629A1 (en)	2018-11-16	2020-05-20	Sandoz AG	Acid addition salts of an integrase strand transfer inhibitor
WO2020161744A1 (en)	2019-02-07	2020-08-13	Cipla Limited	Novel polymorphs of integrase inhibitor
WO2020176505A1 (en)	2019-02-25	2020-09-03	Gilead Sciences, Inc.	Protein kinase c agonists
WO2020176510A1 (en)	2019-02-25	2020-09-03	Gilead Sciences, Inc.	Protein kinase c agonists
AU2020231201A1 (en)	2019-03-07	2021-08-26	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	2'3'-cyclic dinucleotides and prodrugs thereof
KR20210137518A (ko)	2019-03-07	2021-11-17	인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이.	3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
US11766447B2 (en)	2019-03-07	2023-09-26	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
UA127822C2 (uk)	2019-03-22	2024-01-10	Гіліад Сайєнсіз, Інк.	Місткові трициклічні карбамоїлпіридонові сполуки та їх фармацевтичне застосування
TW202212339A (zh)	2019-04-17	2022-04-01	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TW202210480A (zh)	2019-04-17	2022-03-16	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
WO2020214647A1 (en)	2019-04-17	2020-10-22	Gilead Sciences, Inc.	Solid forms of an hiv protease inhibitor
TW202104210A (zh)	2019-04-17	2021-02-01	美商基利科學股份有限公司	Hiv蛋白酶抑制劑
TWI762925B (zh)	2019-05-21	2022-05-01	美商基利科學股份有限公司	鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
CN110229174A (zh) *	2019-05-22	2019-09-13	博诺康源(北京)药业科技有限公司	Bictegravir原料药基因毒性杂质的合成方法
WO2020237025A1 (en)	2019-05-23	2020-11-26	Gilead Sciences, Inc.	Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
RU2717101C1 (ru) *	2019-06-03	2020-03-18	Андрей Александрович Иващенко	Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
CN110263404B (zh) *	2019-06-12	2023-03-21	江苏大学	一种基于dpm模型的一体化预制泵站沉积特性的计算方法
WO2020255038A1 (en)	2019-06-18	2020-12-24	Janssen Sciences Ireland Unlimited Company	Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
EP3993797A4 (en) *	2019-06-18	2023-10-25	Laurus Labs Limited	METHOD AND POLYMORPHOLIC FORMS OF BICTEGRAVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS OR CO-CRYSTALS THEREOF
US20200398978A1 (en)	2019-06-20	2020-12-24	Bell Helicopter Textron Inc.	Low-drag rotor blade extension
AU2020301161B2 (en)	2019-06-25	2023-10-26	Gilead Sciences, Inc.	FLT3L-Fc fusion proteins and methods of use
US11248005B2 (en)	2019-07-08	2022-02-15	Lupin Limited	Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
CA3145791A1 (en)	2019-07-16	2021-01-21	Gilead Sciences, Inc.	Hiv vaccines and methods of making and using
WO2021011891A1 (en)	2019-07-18	2021-01-21	Gilead Sciences, Inc.	Long-acting formulations of tenofovir alafenamide
EP4017476A1 (en)	2019-08-19	2022-06-29	Gilead Sciences, Inc.	Pharmaceutical formulations of tenofovir alafenamide
CN110698473B (zh) *	2019-10-08	2020-12-18	浙江大学	哌嗪酮并羟基吡啶酮-5-羧基类化合物及制备和应用
CA3157275A1 (en)	2019-11-26	2021-06-03	Elena BEKERMAN	Capsid inhibitors for the prevention of hiv
JPWO2021107066A1 (no)	2019-11-28	2021-06-03
JPWO2021107065A1 (no) *	2019-11-28	2021-06-03
BR112022012625A2 (pt)	2019-12-24	2022-09-06	Carna Biosciences Inc	Compostos moduladores de diacilglicerol quinase
MX2022009871A (es)	2020-02-24	2022-08-19	Gilead Sciences Inc	Compuestos tetraciclicos para tratar la infeccion por el virus de la inmunodeficiencia humana (vih).
AU2021237718B2 (en)	2020-03-20	2023-09-21	Gilead Sciences, Inc.	Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
EP4153181A1 (en)	2020-05-21	2023-03-29	Gilead Sciences, Inc.	Pharmaceutical compositions comprising bictegravir
CN113698420A (zh) *	2020-05-22	2021-11-26	上海迪赛诺生物医药有限公司	比克替拉韦钠的新晶型及其制备方法
JP7520162B2 (ja)	2020-06-25	2024-07-22	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｉｖの治療のためのカプシド阻害剤
CR20230071A (es)	2020-08-07	2023-04-11	Gilead Sciences Inc	Profármacos de análogos de nucleótidos de fosfonamida y su uso farmacéutico
JP2023543059A (ja)	2020-09-30	2023-10-12	ギリアードサイエンシーズ，インコーポレイテッド	架橋三環式カルバモイルピリドン化合物及びその使用
TW202406932A (zh)	2020-10-22	2024-02-16	美商基利科學股份有限公司	介白素2-Fc融合蛋白及使用方法
CN114426540B (zh) *	2020-10-29	2024-04-26	上海拓界生物医药科技有限公司	吡啶并[1,2-a]吡嗪-1,8-二酮类前药衍生物、其制备方法及其应用
WO2022089562A1 (zh) *	2020-10-30	2022-05-05	上海拓界生物医药科技有限公司	抑制基因缺陷的hiv病毒的用途
EP4244396A1 (en)	2020-11-11	2023-09-20	Gilead Sciences, Inc.	Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
HRP20231654T1 (hr)	2021-01-19	2024-03-15	Gilead Sciences, Inc.	Supstituirani spojevi piridotriazina i njihove uporabe
US20240309017A1 (en) *	2021-01-22	2024-09-19	Laurus Labs Limited	Processes for purification of bictegravir intermediates
TW202313094A (zh)	2021-05-18	2023-04-01	美商基利科學股份有限公司	使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
JP2024522594A (ja)	2021-06-23	2024-06-21	ギリアードサイエンシーズ，インコーポレイテッド	ジアシルグリセロールキナーゼ調節化合物
KR20240023628A (ko)	2021-06-23	2024-02-22	길리애드 사이언시즈, 인코포레이티드	디아실글리세롤 키나제 조절 화합물
AU2022299051A1 (en)	2021-06-23	2023-12-07	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
KR20240025616A (ko)	2021-06-23	2024-02-27	길리애드 사이언시즈, 인코포레이티드	다이아실글리세롤 키나제 조절 화합물
WO2023006087A1 (zh) *	2021-07-30	2023-02-02	南京明德新药研发有限公司	大环吡啶酮类化合物及其应用
CN114230579A (zh) *	2021-11-12	2022-03-25	南京艾迪医药科技有限公司	多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
MX2024006396A (es)	2021-12-03	2024-06-04	Gilead Sciences Inc	Compuestos terapeuticos para la infeccion por el virus de inmunodeficiencia humana (vih).
KR20240117588A (ko)	2021-12-03	2024-08-01	길리애드 사이언시즈, 인코포레이티드	Hiv 바이러스 감염 치료용 화합물
TW202342447A (zh)	2021-12-03	2023-11-01	美商基利科學股份有限公司	用於ｈｉｖ病毒感染之治療性化合物
CN114605437A (zh) *	2022-04-01	2022-06-10	遵义医科大学	连续一锅法制备三个替拉韦药物的合成工艺
TWI843506B (zh)	2022-04-06	2024-05-21	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2023248240A1 (en)	2022-06-21	2023-12-28	Mylan Laboratories Limited	Polymorphic forms of bictegravir sodium
US20240034724A1 (en)	2022-07-01	2024-02-01	Gilead Sciences, Inc.	Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024015741A1 (en)	2022-07-12	2024-01-18	Gilead Sciences, Inc.	Hiv immunogenic polypeptides and vaccines and uses thereof
US20240083984A1 (en)	2022-08-26	2024-03-14	Gilead Sciences, Inc.	Dosing and scheduling regimen for broadly neutralizing antibodies
WO2024061257A1 (zh) *	2022-09-20	2024-03-28	吉斯凯(苏州)制药有限公司	多环氮杂环酮类化合物及其应用
WO2024076915A1 (en)	2022-10-04	2024-04-11	Gilead Sciences, Inc.	4'-thionucleoside analogues and their pharmaceutical use
WO2024220624A1 (en)	2023-04-19	2024-10-24	Gilead Sciences, Inc.	Dosing regimen of capsid inhibitor

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE788516A (fr)	1971-09-10	1973-03-07	Lonza Ag	Procede de fabrication d'esters alcoxyacetylacetiques
GB1528382A (en)	1974-12-26	1978-10-11	Teijin Ltd	Cyclopentene diols and acyl esters thereof and processes for their preparation
DE2658401A1 (de)	1976-12-23	1978-07-06	Merck Patent Gmbh	Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel
US4575694A (en)	1984-03-05	1986-03-11	Allied Corporation	Coaxial connector
DE3900735A1 (de)	1989-01-12	1990-07-26	Hoechst Ag	Neue mehrfunktionelle (alpha)-diazo-(beta)-ketoester, verfahren zu ihrer herstellung und deren verwendung
US6703396B1 (en)	1990-02-01	2004-03-09	Emory University	Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5914331A (en)	1990-02-01	1999-06-22	Emory University	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en)	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
DE4014649A1 (de)	1990-05-08	1991-11-14	Hoechst Ag	Neue mehrfunktionelle verbindungen mit (alpha)-diazo-ss-ketoester- und sulfonsaeureester-einheiten, verfahren zu ihrer herstellung und deren verwendung
GB9301000D0 (en)	1993-01-20	1993-03-10	Glaxo Group Ltd	Chemical compounds
US5922695A (en)	1996-07-26	1999-07-13	Gilead Sciences, Inc.	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
SE9702772D0 (sv)	1997-07-22	1997-07-22	Astra Pharma Prod	Novel compounds
US5935946A (en)	1997-07-25	1999-08-10	Gilead Sciences, Inc.	Nucleotide analog composition and synthesis method
AU1403099A (en)	1997-11-14	1999-06-07	Merck & Co., Inc.	Alpha-1a adrenergic receptor antagonists
JP2002529455A (ja)	1998-11-09	2002-09-10	ジェームズ・ブラック・ファウンデーション・リミテッド	ガストリンおよびコレシストキニン受容体リガンド類
GB2345058A (en)	1998-12-01	2000-06-28	Cerebrus Pharm Ltd	Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system
CN1178913C (zh)	1998-12-25	2004-12-08	盐野义制药株式会社	具有hiv整合酶抑制活性的芳族杂环化合物
US20040039060A1 (en)	2000-06-14	2004-02-26	Ryuichi Kiyama	Inhibitor for enzyme having two divalent metal ions as active centers
ES2287170T3 (es) *	2000-10-12	2007-12-16	MERCK & CO., INC.	Aza- y poliaza-naftalenil-carboxamidas utilies como inhibidores de la vih integrasa.
KR100977701B1 (ko)	2001-08-10	2010-08-24	시오노기세이야쿠가부시키가이샤	항바이러스제
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
US6727275B2 (en)	2001-10-03	2004-04-27	Ucb, S.A./N.V.	Pyrrolidinone derivatives
PL212914B1 (pl)	2001-10-26	2012-12-31	Angeletti P Ist Richerche Bio	N-podstawione hydroksypirymidynonokarboksyamidy jako inhibitory integrazy HIV
US7109186B2 (en)	2002-07-09	2006-09-19	Bristol-Myers Squibb Company	HIV integrase inhibitors
EP1549315A4 (en)	2002-09-11	2007-05-23	Merck & Co Inc	DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS
SI1564210T1 (sl)	2002-11-20	2010-01-29	Japan Tobacco Inc	4-oksokinolinske spojine in njihova uporaba kot inhibitorji HIV integraze
AP2089A (en)	2003-01-14	2010-01-11	Gilead Sciences Inc	Compositions and methods for combination antiviraltherapy
TW200510425A (en)	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200528440A (en)	2003-10-31	2005-09-01	Fujisawa Pharmaceutical Co	2-cyanopyrrolidinecarboxamide compound
CA2554120A1 (en)	2004-01-30	2005-08-18	Merck & Co., Inc.	N-benzyl-3,4-dihydroxypyridine-2-carboxamide and n-benzyl-2,3-dihydroxypyridine-4-carboxamide compounds useful as hiv integras inhibitors
CA2555176A1 (en)	2004-02-11	2005-08-25	Smithkline Beecham Corporation	Hiv integrase inhibitors
AU2005220767A1 (en)	2004-03-09	2005-09-22	Merck & Co., Inc.	HIV integrase inhibitors
WO2005110399A2 (en)	2004-04-29	2005-11-24	The Regents Of The University Of California	Zinc-binding groups for metalloprotein inhibitors
WO2006028523A2 (en)	2004-04-29	2006-03-16	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN DIEGO USDC Technology Transfer Office	Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors
CN1964975B (zh)	2004-05-07	2011-11-30	默沙东公司	Hiv整合酶抑制剂
US7273859B2 (en)	2004-05-12	2007-09-25	Bristol-Myers Squibb Company	HIV integrase inhibitors: cyclic pyrimidinone compounds
TW200612946A (en) *	2004-05-17	2006-05-01	Tibotec Pharm Ltd	Combinations of substituted 1-phenyl-1,5-dihydro-pyrido-[3,2-b]indol-2-ones and other HIV inhibitors
MY134672A (en)	2004-05-20	2007-12-31	Japan Tobacco Inc	Stable crystal of 4-oxoquinoline compound
WO2005113509A1 (en)	2004-05-20	2005-12-01	Japan Tobacco Inc.	Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
EP2229945A1 (en)	2004-05-21	2010-09-22	Japan Tobacco, Inc.	Combinations comprising a 4-isoquinolone derivative and anti-HIV agents
US7550463B2 (en)	2004-09-15	2009-06-23	Shionogi & Co., Ltd.	Carbamoylpyridone derivatives having inhibitory activity against HIV integrase
JP2006118669A (ja)	2004-10-25	2006-05-11	Sanoh Industrial Co Ltd	樹脂チューブ
WO2006066414A1 (en)	2004-12-23	2006-06-29	Virochem Pharma Inc.	Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
EP1852434B1 (en)	2005-02-21	2011-07-13	Shionogi Co., Ltd.	Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity
DK3284520T3 (da)	2005-04-28	2019-09-16	Viiv Healthcare Co	Polycyklisk carbamoylpyridonderivat med hiv-integrase-hæmmende aktivitet
WO2006125048A2 (en)	2005-05-16	2006-11-23	Gilead Sciences, Inc.	Hiv-integrase inhibitor compounds
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
US20080076740A1 (en)	2005-07-27	2008-03-27	Gilead Sciences, Inc.	Antiviral compounds
TW200800988A (en)	2005-10-27	2008-01-01	Shionogi & Amp Co Ltd	Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
NZ569576A (en)	2005-12-30	2011-09-30	Gilead Sciences Inc	Methods for improving the pharmacokinetics of HIV integrase inhibitors
US7601844B2 (en)	2006-01-27	2009-10-13	Bristol-Myers Squibb Company	Piperidinyl derivatives as modulators of chemokine receptor activity
EP2452682A1 (en)	2006-02-01	2012-05-16	Japan Tobacco, Inc.	Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
NZ570706A (en)	2006-03-06	2010-08-27	Japan Tobacco Inc	Methods for producing an 4-oxoquinoline compound
CN101437801B (zh)	2006-03-06	2013-02-06	日本烟草产业株式会社	制备4-氧代喹啉化合物的方法
US7893055B2 (en)	2006-06-28	2011-02-22	Bristol-Myers Squibb Company	HIV integrase inhibitors
AU2007275805A1 (en)	2006-07-19	2008-01-24	University Of Georgia Research Foundation, Inc.	Pyridinone diketo acids: Inhibitors of HIV replication in combination therapy
EP2069280B1 (en)	2006-09-12	2015-03-25	Gilead Sciences, Inc.	Process and intermediates for preparing HIV integrase inhibitors
WO2008048538A1 (en)	2006-10-18	2008-04-24	Merck & Co., Inc.	Hiv integrase inhibitors
DK3150586T3 (da)	2007-02-23	2020-02-17	Gilead Sciences Inc	Modulatorer af farmakokinetiske egenskaber af terapeutika
US20080280945A1 (en)	2007-05-09	2008-11-13	Sachin Lohani	Crystalline forms of an HIV integrase inhibitor
CN101743004A (zh)	2007-06-29	2010-06-16	吉里德科学公司	治疗用组合物及其用途
AP2965A (en)	2007-06-29	2014-09-30	Gilead Sciences Inc	Therapeutic compositions and the use thereof
US20090012103A1 (en)	2007-07-05	2009-01-08	Matthew Abelman	Substituted heterocyclic compounds
WO2009018320A1 (en)	2007-07-31	2009-02-05	Limerick Biopharma, Inc.	Pyrone analog compositions and methods
AR068403A1 (es)	2007-09-11	2009-11-18	Gilead Sciences Inc	Proceso e intermediarios para la preparacion de inhibidores de integrasa
CA2707418C (en)	2007-11-16	2013-11-19	Boehringer Ingelheim International Gmbh	Inhibitors of human immunodeficiency virus replication
GB0803019D0 (en)	2008-02-19	2008-03-26	Btg Int Ltd	Fluorinated compounds
US8129398B2 (en)	2008-03-19	2012-03-06	Bristol-Myers Squibb Company	HIV integrase inhibitors
WO2010011813A1 (en)	2008-07-23	2010-01-28	Alkermes, Inc.	Complex of trospium and pharmaceutical compositions thereof
CN105198804B (zh)	2008-07-25	2018-03-23	盐野义制药株式会社	用作hiv整合酶抑制剂的化合物
WO2010011812A1 (en)	2008-07-25	2010-01-28	Smithkline Beecham Corporation	Chemical compounds
WO2010011815A1 (en)	2008-07-25	2010-01-28	Smithkline Beecham Corporation	Chemical compounds
EP2330902B1 (en)	2008-07-25	2012-11-14	GlaxoSmithKline LLC	Chemical compounds
WO2010011818A1 (en)	2008-07-25	2010-01-28	Smithkline Beecham Corporation	Chemical compounds
WO2010011819A1 (en)	2008-07-25	2010-01-28	Smithkline Beecham Corporation	Chemical compounds
JP5572168B2 (ja)	2008-12-11	2014-08-13	ビーブ・ヘルスケア・カンパニー	カルバモイルピリドンｈｉｖインテグラーゼ阻害剤の製造方法および中間体
ES2641765T3 (es)	2008-12-11	2017-11-13	Shionogi & Co., Ltd.	Síntesis de inhibidores de integrasa de VIH carbamoilpiridona y productos intermedios
EP2367821B1 (en)	2008-12-17	2015-09-16	Merck Patent GmbH	C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
AU2010210598B2 (en)	2009-02-06	2015-03-05	Gilead Sciences, Inc.	Tablets for combination therapy
WO2010110231A1 (ja)	2009-03-26	2010-09-30	塩野義製薬株式会社	置換された３－ヒドロキシ－４－ピリドン誘導体
TWI518084B (zh) *	2009-03-26	2016-01-21	鹽野義製藥股份有限公司	哌喃酮與吡啶酮衍生物之製造方法
WO2010147068A1 (ja)	2009-06-15	2010-12-23	塩野義製薬株式会社	置換された多環性カルバモイルピリドン誘導体
WO2011028044A2 (ko)	2009-09-02	2011-03-10	이화여자대학교 산학협력단	피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물
EP3351249A1 (en)	2010-01-27	2018-07-25	VIIV Healthcare Company	Antiviral therapy
US10065950B2 (en)	2010-02-26	2018-09-04	Japan Tobacco Inc.	Substituted thiazoles as HIV integrase inhibitors
TWI582097B (zh)	2010-03-23	2017-05-11	Ｖｉｉｖ醫療保健公司	製備胺甲醯吡啶酮衍生物及中間體之方法
WO2011139637A1 (en)	2010-05-03	2011-11-10	Philadelphia Health & Education Corporation	Small-molecule modulators of hiv-1 capsid stability and methods thereof
SG186820A1 (en)	2010-07-02	2013-02-28	Gilead Sciences Inc	Napht- 2 -ylacetic acid derivatives to treat aids
MX2012015293A (es)	2010-07-02	2013-05-30	Gilead Sciences Inc	Derivados de acido 2-quinolinil-acetico como compuestos antivirales.
US20130210809A1 (en)	2010-07-14	2013-08-15	Christelle Boléa	Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
LT3456721T (lt)	2010-08-05	2021-07-12	Shionogi & Co., Ltd	Junginių, pasižyminčių živ integrazės inhibavimo aktyvumu, gavimo būdas
LT2620436T (lt)	2010-09-24	2018-08-10	Shionogi & Co., Ltd.	Pakeistojo policiklinio karbamoilpiridono darinio provaistas
KR101923103B1 (ko)	2010-11-19	2018-11-28	길리애드 사이언시즈, 인코포레이티드	릴피비린 hcl 및 테노포비어 디소프록실 푸마레이트를 포함하는 치료 조성물
WO2012106534A2 (en)	2011-02-02	2012-08-09	The Regents Of The University Of California	Hiv integrase inhibitors
CN105712948A (zh)	2011-04-21	2016-06-29	吉利德科学公司	苯并噻唑化合物及其药学上的应用
WO2012151361A1 (en)	2011-05-03	2012-11-08	Concert Pharmaceuticals Inc.	Carbamoylpyridone derivatives
US9328075B2 (en)	2011-05-05	2016-05-03	St. Jude Children's Research Hospital	Pyrimidinone compounds and methods for treating influenza
US9121496B2 (en)	2011-06-29	2015-09-01	Arvinmeritor Technology, Llc	Drive axle system and a method of control
US9540343B2 (en)	2011-07-06	2017-01-10	Gilead Sciences, Inc.	Compounds for the treatment of HIV
NO2729130T3 (no)	2011-07-07	2018-02-03
CN102863512B (zh)	2011-07-07	2016-04-20	上海泓博智源医药技术有限公司	抗病毒化合物
ES2613180T3 (es)	2011-09-14	2017-05-23	Mapi Pharma Limited	Forma amorfa de la sal sódica dolutegravir
BR112014008896A2 (pt)	2011-10-12	2017-04-18	Shionogi & Co	derivado de piridona policíclico tendo atividade inibidora de integrase
EP2804864B1 (en)	2011-12-12	2017-09-06	Bayer Intellectual Property GmbH	Amino-substituted imidazopyridazines
US9284323B2 (en)	2012-01-04	2016-03-15	Gilead Sciences, Inc.	Naphthalene acetic acid derivatives against HIV infection
WO2014008636A1 (en)	2012-07-11	2014-01-16	Merck Sharp & Dohme Corp.	Macrocyclic compounds as hiv integrase inhibitors
US20150166520A1 (en)	2012-07-20	2015-06-18	Merck Sharp & Dohme Corp.	Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
EP2877469A4 (en)	2012-07-25	2016-04-06	Merck Sharp & Dohme	SUBSTITUTED NAPHTHYRIDINEDIONE DERIVATIVES AS INHIBITORS OF HIV INTEGRASE
SG11201500812QA (en)	2012-08-03	2015-04-29	Gilead Sciences Inc	Process and intermediates for preparing integrase inhibitors
BR112015009850A2 (pt)	2012-11-08	2017-07-11	Bristol Myers Squibb Co	compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
SG10201704467SA (en)	2012-12-14	2017-06-29	Glaxosmithkline Llc	Pharmaceutical compositions
EP2931730B1 (en)	2012-12-17	2019-08-07	Merck Sharp & Dohme Corp.	4-pyridinonetriazine derivatives as hiv integrase inhibitors
US20140221355A1 (en)	2012-12-21	2014-08-07	Gilead Sciences, Inc.	Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
KR101770048B1 (ko)	2012-12-21	2017-08-21	길리애드 사이언시즈, 인코포레이티드	폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
EP2934482A4 (en)	2012-12-21	2016-07-20	Merck Sharp & Dohme	ADMINISTRATIVE FORMULATIONS
CA2890290A1 (en)	2012-12-27	2014-07-03	Japan Tobacco Inc.	Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as hiv integrase inhibitor
WO2014172188A2 (en)	2013-04-16	2014-10-23	Merck Sharp & Dohme Corp.	4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
WO2014200880A1 (en)	2013-06-13	2014-12-18	Merck Sharp & Dohme Corp.	Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
EP3252058B1 (en)	2013-07-12	2021-01-20	Gilead Sciences, Inc.	Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
NO2865735T3 (no)	2013-07-12	2018-07-21
WO2015039348A1 (en)	2013-09-23	2015-03-26	Merck Sharp & Dohme Corp.	Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
KR101809392B1 (ko)	2013-09-27	2017-12-14	머크 샤프 앤드 돔 코포레이션	Hiv 인테그라제 억제제로서 유용한 치환된 퀴놀리진 유도체
WO2015089847A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
IN2014CH00247A (no)	2014-01-21	2015-08-14	Laurus Labs Private Ltd
WO2015138933A1 (en)	2014-03-13	2015-09-17	Assia Chemical Industries Ltd.	Solid state forms of dolutegravir sodium
TWI677489B (zh)	2014-06-20	2019-11-21	美商基利科學股份有限公司	多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en)	2014-06-20	2016-04-16	Gilead Sciences Inc	Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (no)	2014-06-20	2018-06-23
SG11201700070QA (en) *	2014-07-11	2017-02-27	Gilead Sciences Inc	Modulators of toll-like receptors for the treatment of hiv
TWI695003B (zh)	2014-12-23	2020-06-01	美商基利科學股份有限公司	多環胺甲醯基吡啶酮化合物及其醫藥用途
ES2718410T3 (es)	2015-04-02	2019-07-01	Gilead Sciences Inc	Compuestos de carbamoilpiridonas policíclicos y su utilización farmacéutica
CA2921336A1 (en)	2015-06-30	2016-12-30	Gilead Sciences, Inc.	Pharmaceutical formulations
PL4070787T3 (pl)	2015-06-30	2023-07-24	Gilead Sciences, Inc.	Formulacje farmaceutyczne
EA201890654A1 (ru)	2015-11-09	2018-10-31	Джилид Сайэнс, Инк.	Терапевтические композиции для лечения вируса иммунодефицита человека

2013
- 2013-12-19 KR KR1020157019194A patent/KR101770048B1/ko active IP Right Grant
- 2013-12-19 PL PL15201519T patent/PL3067358T3/pl unknown
- 2013-12-19 WO PCT/US2013/076367 patent/WO2014100323A1/en active Application Filing
- 2013-12-19 MD MDA20170067A patent/MD4754C1/ro active IP Right Grant
- 2013-12-19 LT LTEP19185121.1T patent/LT3608325T/lt unknown
- 2013-12-19 PE PE2015001036A patent/PE20151499A1/es active IP Right Grant
- 2013-12-19 CA CA3012242A patent/CA3012242C/en active Active
- 2013-12-19 TW TW102147242A patent/TWI642669B/zh active
- 2013-12-19 ES ES19185121T patent/ES2926068T3/es active Active
- 2013-12-19 MX MX2017000362A patent/MX357940B/es unknown
- 2013-12-19 EP EP22178867.2A patent/EP4122935A1/en active Pending
- 2013-12-19 AP AP2015008510A patent/AP2015008510A0/xx unknown
- 2013-12-19 PT PT191851211T patent/PT3608325T/pt unknown
- 2013-12-19 PT PT138159371T patent/PT2822954E/pt unknown
- 2013-12-19 CN CN202010188107.9A patent/CN111303152B/zh active Active
- 2013-12-19 JP JP2015549669A patent/JP6028105B2/ja active Active
- 2013-12-19 EA EA201591027A patent/EA030003B1/ru active Protection Beyond IP Right Term
- 2013-12-19 DK DK13815937.1T patent/DK2822954T3/en active
- 2013-12-19 AR ARP130104930A patent/AR094197A1/es active IP Right Grant
- 2013-12-19 NZ NZ709260A patent/NZ709260A/en unknown
- 2013-12-19 KR KR1020207015960A patent/KR102246963B1/ko active IP Right Grant
- 2013-12-19 TW TW112109785A patent/TWI830624B/zh active
- 2013-12-19 DK DK19185121.1T patent/DK3608325T3/da active
- 2013-12-19 PL PL13815937.1T patent/PL2822954T3/pl unknown
- 2013-12-19 EP EP19185121.1A patent/EP3608325B1/en active Active
- 2013-12-19 PL PL19185121.1T patent/PL3608325T3/pl unknown
- 2013-12-19 CN CN201711080644.6A patent/CN107674086B/zh active Active
- 2013-12-19 HR HRP20220899TT patent/HRP20220899T1/hr unknown
- 2013-12-19 ES ES13815937.1T patent/ES2577283T3/es active Active
- 2013-12-19 HU HUE15201519A patent/HUE046559T2/hu unknown
- 2013-12-19 UA UAA201612380A patent/UA123572C2/uk unknown
- 2013-12-19 EP EP13815937.1A patent/EP2822954B1/en active Active
- 2013-12-19 TW TW109111537A patent/TWI752457B/zh active
- 2013-12-19 ME MEP-2016-93A patent/ME02400B/me unknown
- 2013-12-19 NZ NZ718708A patent/NZ718708A/en unknown
- 2013-12-19 RS RS20160407A patent/RS54873B1/sr unknown
- 2013-12-19 US US14/133,858 patent/US9216996B2/en active Active
- 2013-12-19 TW TW107127529A patent/TWI693224B/zh active
- 2013-12-19 LT LT15201519T patent/LT3067358T/lt unknown
- 2013-12-19 PT PT152015194T patent/PT3067358T/pt unknown
- 2013-12-19 MD MDA20200093A patent/MD4841B1/ro not_active IP Right Cessation
- 2013-12-19 KR KR1020227018650A patent/KR102527797B1/ko active IP Right Grant
- 2013-12-19 CN CN201380073134.XA patent/CN104995198B/zh active Active
- 2013-12-19 ES ES15201519T patent/ES2753548T3/es active Active
- 2013-12-19 KR KR1020237014240A patent/KR20230061576A/ko not_active Application Discontinuation
- 2013-12-19 MY MYPI2015001580A patent/MY164352A/en unknown
- 2013-12-19 CN CN202310322212.0A patent/CN116640140A/zh active Pending
- 2013-12-19 KR KR1020197031864A patent/KR102120875B1/ko active IP Right Grant
- 2013-12-19 HU HUE19185121A patent/HUE059688T2/hu unknown
- 2013-12-19 UY UY35213A patent/UY35213A/es not_active Application Discontinuation
- 2013-12-19 MX MX2015008009A patent/MX344879B/es active IP Right Grant
- 2013-12-19 DK DK15201519T patent/DK3067358T3/da active
- 2013-12-19 SI SI201332004T patent/SI3608325T1/sl unknown
- 2013-12-19 MD MDA20150064A patent/MD4736C1/ro active IP Right Grant
- 2013-12-19 BR BR112015014714-3A patent/BR112015014714B1/pt active IP Right Grant
- 2013-12-19 CA CA2893843A patent/CA2893843C/en active Active
- 2013-12-19 EA EA201890236A patent/EA037633B1/ru unknown
- 2013-12-19 KR KR1020217012463A patent/KR102351912B1/ko active IP Right Grant
- 2013-12-19 EP EP15201519.4A patent/EP3067358B1/en active Active
- 2013-12-19 SI SI201331609T patent/SI3067358T1/sl unknown
- 2013-12-19 CR CR20170279A patent/CR20170279A/es unknown
- 2013-12-19 MY MYPI2016001880A patent/MY191741A/en unknown
- 2013-12-19 SI SI201330197A patent/SI2822954T1/sl unknown
- 2013-12-19 AU AU2013361401A patent/AU2013361401C1/en active Active
- 2013-12-19 UA UAA201506209A patent/UA114351C2/uk unknown
- 2013-12-19 CA CA3131094A patent/CA3131094A1/en active Pending
- 2013-12-19 BR BR122015029881-4A patent/BR122015029881B1/pt active IP Right Grant
- 2013-12-19 KR KR1020177016697A patent/KR102040007B1/ko active IP Right Grant
- 2013-12-19 HU HUE13815937A patent/HUE028284T2/en unknown
- 2013-12-19 PH PH12019501848A patent/PH12019501848A1/en unknown
- 2013-12-19 KR KR1020227001078A patent/KR102406288B1/ko active IP Right Grant
- 2013-12-19 SG SG11201504857SA patent/SG11201504857SA/en unknown
- 2013-12-19 TW TW110146626A patent/TWI815245B/zh active
- 2013-12-19 PE PE2016000694A patent/PE20170528A1/es unknown
2015
- 2015-06-10 IL IL239316A patent/IL239316A/en active IP Right Grant
- 2015-06-18 MX MX2020003055A patent/MX2020003055A/es unknown
- 2015-06-18 MX MX2022013596A patent/MX2022013596A/es unknown
- 2015-06-18 CL CL2015001756A patent/CL2015001756A1/es unknown
- 2015-06-22 PH PH12015501445A patent/PH12015501445B1/en unknown
- 2015-06-22 HK HK15105909.2A patent/HK1205124A1/xx unknown
- 2015-07-17 CR CR20150380A patent/CR20150380A/es unknown
- 2015-07-31 US US14/815,504 patent/US9663528B2/en active Active
- 2015-10-26 ZA ZA2015/07997A patent/ZA201507997B/en unknown
2016
- 2016-02-29 PH PH12016500389A patent/PH12016500389B1/en unknown
- 2016-04-11 CL CL2016000837A patent/CL2016000837A1/es unknown
- 2016-04-21 HK HK16104629.3A patent/HK1216643A1/zh unknown
- 2016-04-21 HK HK18110106.0A patent/HK1250711A1/zh unknown
- 2016-05-20 HR HRP20160544TT patent/HRP20160544T1/hr unknown
- 2016-05-23 IL IL245780A patent/IL245780B/en active IP Right Grant
- 2016-05-30 CY CY20161100472T patent/CY1117570T1/el unknown
- 2016-06-01 SM SM201600157T patent/SMT201600157B/it unknown
- 2016-06-21 JP JP2016122743A patent/JP6411409B2/ja active Active
- 2016-08-17 IL IL247311A patent/IL247311A0/en unknown
- 2016-11-11 US US15/349,934 patent/US9732092B2/en active Active
- 2016-11-24 AU AU2016262722A patent/AU2016262722B2/en active Active
2017
- 2017-05-11 CL CL2017001191A patent/CL2017001191A1/es unknown
- 2017-05-18 US US15/599,151 patent/US10035809B2/en active Active
2018
- 2018-06-25 US US16/017,371 patent/US10689399B2/en active Active
- 2018-08-17 LU LU00083C patent/LUC00083I2/en unknown
- 2018-08-21 LT LTPA2018511C patent/LTC2822954I2/lt unknown
- 2018-08-22 NL NL300947C patent/NL300947I2/nl unknown
- 2018-08-23 CY CY2018022C patent/CY2018022I1/el unknown
- 2018-08-23 HU HUS1800035C patent/HUS1800035I1/hu unknown
- 2018-08-23 NO NO2018026C patent/NO2018026I1/no unknown
- 2018-09-19 AU AU2018232957A patent/AU2018232957B2/en active Active
- 2018-09-26 JP JP2018179844A patent/JP6571256B2/ja active Active
2019
- 2019-02-22 ZA ZA2019/03516A patent/ZA201903516B/en unknown
- 2019-08-07 JP JP2019145317A patent/JP6933690B2/ja active Active
- 2019-10-29 HR HRP20191957TT patent/HRP20191957T1/hr unknown
- 2019-11-05 CY CY20191101151T patent/CY1122246T1/el unknown
2020
- 2020-05-01 AU AU2020202914A patent/AU2020202914B2/en active Active
- 2020-05-06 US US16/868,119 patent/US11548901B2/en active Active
- 2020-05-28 IL IL274988A patent/IL274988A/en unknown
2021
- 2021-08-19 JP JP2021134172A patent/JP7301918B2/ja active Active
- 2021-08-23 AU AU2021221427A patent/AU2021221427B2/en active Active
2023
- 2023-06-21 JP JP2023101636A patent/JP2023134483A/ja active Pending
- 2023-12-30 AU AU2023286038A patent/AU2023286038A1/en active Pending

Also Published As

Publication number	Publication date
PH12016500389A1 (en)	2018-10-01
AU2016262722A1 (en)	2016-12-08
EP3067358B1 (en)	2019-08-07
MD4754B1 (ro)	2021-05-31
EP2822954A1 (en)	2015-01-14
AU2020202914A1 (en)	2020-05-21
CN107674086B (zh)	2020-03-31
EA201591027A1 (ru)	2016-05-31
CN111303152B (zh)	2023-04-11
PL3608325T3 (pl)	2022-11-07
KR20170073733A (ko)	2017-06-28
IL247311A0 (en)	2016-09-29
TWI830624B (zh)	2024-01-21
ME02400B (me)	2016-09-20
TW202212342A (zh)	2022-04-01
HUE046559T2 (hu)	2020-03-30
ES2753548T3 (es)	2020-04-13
IL274988A (en)	2020-07-30
CN104995198B (zh)	2018-01-30
BR112015014714B1 (pt)	2018-12-26
HRP20191957T1 (hr)	2020-02-07
AU2018232957B2 (en)	2020-01-30
CR20150380A (es)	2015-08-21
LTPA2018511I1 (lt)	2018-10-10
US9216996B2 (en)	2015-12-22
US9663528B2 (en)	2017-05-30
NO2018026I2 (no)	2018-08-23
KR20220080208A (ko)	2022-06-14
MY191741A (en)	2022-07-13
HUE028284T2 (en)	2016-12-28
KR20230061576A (ko)	2023-05-08
MD4841B1 (ro)	2023-01-31
PT3608325T (pt)	2022-10-17
DK3608325T3 (da)	2022-08-22
EP4122935A1 (en)	2023-01-25
PL2822954T3 (pl)	2016-09-30
JP6933690B2 (ja)	2021-09-08
JP2016179996A (ja)	2016-10-13
RS54873B1 (sr)	2016-10-31
BR122015029881B1 (pt)	2022-04-26
AU2021221427A1 (en)	2021-09-16
MX2015008009A (es)	2015-10-22
TW201441224A (zh)	2014-11-01
UA114351C2 (uk)	2017-05-25
LT3067358T (lt)	2019-11-25
EP3608325A1 (en)	2020-02-12
JP2021193090A (ja)	2021-12-23
SMT201600157B (it)	2016-08-31
WO2014100323A1 (en)	2014-06-26
KR102406288B1 (ko)	2022-06-13
KR20190124814A (ko)	2019-11-05
LT3608325T (lt)	2022-09-12
MD4754C1 (ro)	2021-12-31
BR112015014714A2 (pt)	2016-01-05
PT2822954E (pt)	2016-06-16
UY35213A (es)	2014-06-30
AU2023286038A1 (en)	2024-01-25
PL3067358T3 (pl)	2020-02-28
CL2017001191A1 (es)	2018-02-09
CN107674086A (zh)	2018-02-09
CA3131094A1 (en)	2014-06-26
KR102040007B1 (ko)	2019-11-05
TW202400591A (zh)	2024-01-01
NL300947I2 (nl)	2018-09-26
DK3067358T3 (da)	2019-11-04
TW201918485A (zh)	2019-05-16
ES2577283T3 (es)	2016-07-14
ZA201903516B (en)	2020-01-29
CN111303152A (zh)	2020-06-19
CA2893843A1 (en)	2014-06-26
CY1122246T1 (el)	2020-11-25
CN104995198A (zh)	2015-10-21
ES2926068T3 (es)	2022-10-21
AR094197A1 (es)	2015-07-15
TWI693224B (zh)	2020-05-11
JP7301918B2 (ja)	2023-07-03
JP6571256B2 (ja)	2019-09-04
KR102527797B1 (ko)	2023-05-03
KR102120875B1 (ko)	2020-06-09
KR20220011789A (ko)	2022-01-28
AU2020202914B2 (en)	2021-09-09
CN116640140A (zh)	2023-08-25
MX357940B (es)	2018-07-31
IL245780B (en)	2019-02-28
TWI815245B (zh)	2023-09-11
PE20151499A1 (es)	2015-10-29
HK1216643A1 (zh)	2016-11-25
LTC2822954I2 (lt)	2019-10-10
AU2013361401C1 (en)	2018-08-09
MX2020003055A (es)	2020-07-27
IL239316A (en)	2016-09-29
KR101770048B1 (ko)	2017-08-21
US20170260204A1 (en)	2017-09-14
CA3012242C (en)	2021-11-02
US20190092787A1 (en)	2019-03-28
PH12019501848A1 (en)	2020-03-02
IL245780A0 (en)	2016-08-02
CL2015001756A1 (es)	2015-08-07
NZ718708A (en)	2018-11-30
AU2021221427B2 (en)	2023-10-12
CL2016000837A1 (es)	2016-10-21
US20160176885A1 (en)	2016-06-23
ZA201507997B (en)	2019-09-25
AU2018232957A1 (en)	2018-10-11
KR20200067930A (ko)	2020-06-12
US11548901B2 (en)	2023-01-10
US20170057976A1 (en)	2017-03-02
AP2015008510A0 (en)	2015-06-30
TW202104229A (zh)	2021-02-01
EP3608325B1 (en)	2022-07-06
TWI752457B (zh)	2022-01-11
SI2822954T1 (sl)	2016-07-29
HK1205124A1 (en)	2015-12-11
EA037633B1 (ru)	2021-04-23
HRP20220899T1 (hr)	2022-10-28
KR20210049956A (ko)	2021-05-06
CA2893843C (en)	2018-09-04
MD20200093A2 (ro)	2021-05-31
KR102351912B1 (ko)	2022-01-17
NZ709260A (en)	2016-07-29
AU2013361401A1 (en)	2015-08-27
PT3067358T (pt)	2019-11-18
SI3608325T1 (sl)	2022-09-30
HK1250711A1 (zh)	2019-01-11
JP6028105B2 (ja)	2016-11-16
HRP20160544T1 (hr)	2016-07-15
AU2013361401B2 (en)	2017-01-05
MD20150064A2 (ro)	2015-11-30
US9732092B2 (en)	2017-08-15
CY1117570T1 (el)	2017-04-26
SI3067358T1 (sl)	2019-12-31
US20210053988A1 (en)	2021-02-25
SG11201504857SA (en)	2015-07-30
JP6411409B2 (ja)	2018-10-24
PH12015501445A1 (en)	2015-09-14
TWI642669B (zh)	2018-12-01
HUE059688T2 (hu)	2022-12-28
EP2822954B1 (en)	2016-03-09
JP2019218368A (ja)	2019-12-26
JP2023134483A (ja)	2023-09-27
KR20150096504A (ko)	2015-08-24
MD4736C1 (ro)	2021-07-31
LUC00083I2 (en)	2018-10-15
US10035809B2 (en)	2018-07-31
US20140221356A1 (en)	2014-08-07
EP3067358A1 (en)	2016-09-14
CR20170279A (es)	2017-10-19
IL239316A0 (en)	2015-07-30
BR122015029881A2 (pt)	2016-03-22
AU2016262722B2 (en)	2018-10-18
KR102246963B1 (ko)	2021-04-30
DK2822954T3 (en)	2016-05-30
PE20170528A1 (es)	2017-05-28
MX344879B (es)	2017-01-11
JP2019023204A (ja)	2019-02-14
MX2022013596A (es)	2022-11-16
UA123572C2 (uk)	2021-04-28
EA030003B1 (ru)	2018-06-29
CA3012242A1 (en)	2014-06-26
MD4736B1 (ro)	2020-12-31
CY2018022I2 (el)	2019-07-10
MY164352A (en)	2017-12-15
HUS1800035I1 (hu)	2018-09-28
PH12015501445B1 (en)	2015-09-14
EA201890236A1 (ru)	2018-10-31
PH12016500389B1 (en)	2018-10-01
CY2018022I1 (el)	2019-07-10
JP2016508134A (ja)	2016-03-17
US10689399B2 (en)	2020-06-23

Publication	Publication Date	Title
NO2018026I2 (no)	2018-08-23	Bictegravir eller et farmasøytisk akseptabelt salt derav, spesielt natriumbictegravir
NO2022044I1 (no)	2022-10-27	daridorexant eller et farmasøytisk akseptabelt salt derav, spesielt daridorexant hydroklorid
NO2022010I1 (no)	2022-04-07	ripretinib, or a pharmaceutically acceptable salt thereof
NO2021034I1 (no)	2021-09-09	pemigatinib or a pharmaceutically acceptable salt thereof
NO2021033I1 (no)	2021-09-06	Selineksor eller et farmasøytisk akseptabelt salt derav
NO2024001I1 (no)	2024-01-09	Ritlecitinib, or a pharmaceutically acceptable salt thereof
NO2022004I1 (no)	2022-02-01	abrocitinib, or a pharmaceutically acceptable salt thereof
NO2021041I1 (no)	2021-09-20	remimazolam or a pharmaceutically acceptable salt thereof
NO2023046I1 (no)	2023-12-20	Futibatinib eller et salt derav
NO2024042I1 (no)	2024-09-30	Iptacopan or a pharmaceutically acceptable salt thereof
NO2023043I1 (no)	2023-12-01	Mavacamten or a pharmaceutically acceptable salt thereof
NO2022005I1 (no)	2022-02-03	Zanubrutinib or a pharmaceutically acceptable salt thereof
FIC20230028I1 (fi)	2023-08-28	Deukravasitinibi tai sen framaseuttisesti hyväksyttävä suola
NO2023023I1 (no)	2023-05-24	Maralixibat, or a pharmaceutically acceptable salt thereof, in particular maralixibat chloride
NO2022031I1 (no)	2022-07-20	Voxelotor or a tautomer or pharmaceutically acceptable salt thereof
FIC20240012I1 (fi)	2024-04-18	Omaveloksoloni tai sen farmaseuttisesti hyväksyttävä suola
NL301201I2 (nl)	2022-12-07	Asciminib of een farmaceutisch aanvaardbaar zout daarvan, zoals asciminibhydrochloride
NO2023038I1 (no)	2023-10-13	Ivosidenib or a pharmaceutically acceptable salt, tautomer, isotopologue or hydrate thereof
NO2017057I1 (no)	2017-11-10	pibrentasvir eller et farmasøytisk akseptabelt salt derav
NO2023040I1 (no)	2023-10-20	Atogepant or a pharmaceutically acceptable salt thereof
NL300976I1 (nl)	2019-04-03	natriumzirkoniumcyclosilicaat
FIC20240022I1 (fi)	2024-06-19	Retsafungiini tai sen farmaseuttisesti hyväksyttävä suola, erityisesti retsafungiiniasetaatti
NO2019019I1 (no)	2019-04-24	Doravirin eller et farmasøytisk akseptabelt salt derav
NO2020029I1 (no)	2020-08-26	Givosiran eller et farmasøytisk akseptabelt salt derav
NO2015012I2 (no)	2015-04-22	Ombitasvir, eller et farmasøytisk akseptabelt salt derav